Remove Biotech Remove Marketing Remove Technology
article thumbnail

Deep tech disruption: How advanced technologies are transforming businesses

CIO

From AI models that boost sales to robots that slash production costs, advanced technologies are transforming both top-line growth and bottom-line efficiency. Business leaders dont need to be technology experts to grasp this shift; they need vision and urgency. The path from lab to market keeps shortening.

article thumbnail

The Week’s 10 Biggest Funding Rounds: Crusoe Energy, Insider And Biotech Raise Big

Crunchbase News

startups raised half a billion dollars apiece, and another eight raised $100 million or more, with industries from cybersecurity to biotech to AI represented. tied) Insider , $500M, digital marketing: Marketing tech platform Insider raised a $500 million Series E led by General Atlantic to fund its expansion in the U.S.

Biotech 129
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

In an increasingly hot biotech market, protecting IP is key

TechCrunch

2021 should be a banner year for biotech startups that make smart choices early. After a record year for biotech investment in 2020 — during which the industry saw $28.5 billion invested across 1,073 deals — the market for new innovations remains strong. More posts by this contributor. Kevin O’Connor. Contributor.

Biotech 240
article thumbnail

5 strategies for biotech startups to outlast a market downturn

TechCrunch

James Coates is the Health and Human Performance principal at Decisive Point , a venture capital and advisory firm that invests in and supports startups with emerging defense technologies. Inflationary market dynamics and ongoing fiscal tightening continue to pose significant risks to capital commitments.

Biotech 231
article thumbnail

IPO Readiness: What Biotech Startups And Others Need To Know

Crunchbase News

Given this success, many biotech companies are looking to move on to the next phase of their organizational growth — which may mean an initial public offering. As optimism grows, market conditions may stabilize in 2025 — particularly in the wake of the recent interest rate cuts — and more biotech companies may consider offerings.

Biotech 100
article thumbnail

6 investors discuss why AI is more than just a buzzword in biotech

TechCrunch

That’s why we weren’t very surprised when a slew of investors told us they rarely see a biotech startup that doesn’t incorporate AI in some form or other these days. But despite becoming quite the buzzword, AI’s apparent ubiquity in biotech isn’t actually driving deal flow or higher valuations.

Biotech 242
article thumbnail

These Were The Winners And Losers In A Boring Year For Startup IPOs

Crunchbase News

tech unicorns made it to market. Biotech offerings, while more plentiful, are also running well below prior highs. Below, we pick out winners and losers for venture-backed tech and biotech companies, focusing on large- and medium-sized IPOs. footnote]since the companys March IPO , delivering a market cap around $26 billion.

Biotech 123